Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

Introduction: Malignant pleural effusion (MPE) is associated with poor treatment outcome in patients with NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy (ICI/Chemo) combination therapy is currently the standard therapy for NSCLC, and some ICI/Chemo regimens for nonsquamou...

Full description

Bibliographic Details
Main Authors: Hayato Kawachi, MD, Motohiro Tamiya, MD, Yoshihiko Taniguchi, MD, Toshihide Yokoyama, MD, Shinya Yokoe, MD, Yuko Oya, MD, PhD, Mihoko Imaji, MD, Fukuko Okabe, MD, Masaki Kanazu, MD, Yoshihiko Sakata, MD, Shinya Uematsu, MD, Satoshi Tanaka, MD, Daisuke Arai, MD, PhD, Go Saito, MD, Hiroshi Kobe, MD, Eisaku Miyauchi, MD, PhD, Asuka Okada, MD, PhD, Satoshi Hara, MD, Toru Kumagai, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:JTO Clinical and Research Reports
Subjects:
Immune checkpoint inhibitor
Combination therapy
Non–small cell lung cancer
Malignant pleural effusion
Treatment outcome
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322000790

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322000790

Similar Items